Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief

PHASE4CompletedINTERVENTIONAL
Enrollment

1,220

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Asthma
Interventions
DRUG

PARTICS using QVAR

Patient takes inhaled corticosteroid at the time of rescue inhaler use

Trial Locations (20)

10029

Mt. Sinai, New York

10461

Montefiore, The Bronx

19104

University of Pennsylvania, Philadelphia

19122

Temple University, Philadelphia

25799

University of North Carolina, Chapel Hill

27705

Duke University, Durham

28207

Atrium Health, Charlotte

32610

University of Florida, Gainesville

32827

Grace Medical Home, Orlando

University of Central Florida, Orlando

33136

University of Miami, Miami

33613

University of South Florida, Tampa

35294

University of Alabama, Birmingham

44109

MetroHealth, Cleveland

60607

University of Illinois- Chicago, Chicago

80209

Denver Health and Hospital Authority, Denver

90033

University of Southern California, Los Angeles

06510

Yale University, New Haven

01199

Baystate Health Center, Springfield

00926

University of Puerto Rico, San Juan

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

American Academy of Family Physicians

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT02995733 - Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief | Biotech Hunter | Biotech Hunter